Advances in ocular drug delivery

Current Eye Research

Volumn 37, Issue 5, 2012, Pages 345-356

  Rawas Qalaji, Mutasem ^a   Williams, Cheryl Ann ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Anterior of the eye; Eye drops; Gene therapy; Intravitreal; Iontophoresis; Microemulsions; Ocular drug delivery; Ocular inserts; Posterior of the eye; Sub conjunctival

Indexed keywords

ACICLOVIR; AGENTS ACTING ON THE EYE; CIPROFLOXACIN; CYCLOSPORIN; CYCLOSPORIN A; DEXAMETHASONE; DICLOFENAC; DIPALMITOYLPHOSPHATIDYLCHOLINE; ERYTHROMYCIN; FLUOCINOLONE ACETONIDE; FOMIVIRSEN; GANCICLOVIR; GATIFLOXACIN; HYDROCORTISONE; HYDROXYPROPYLCELLULOSE; METHYLPREDNISOLONE; MOXIFLOXACIN; NT 501; PADELIPORFIN; PEGAPTANIB; PEPTIDE TRANSPORTER 2; PILOCARPINE; PIROXICAM; PRADOFLOXACIN; PREDNISOLONE; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERLUKAST; VERTEPORFIN;

ANTERIOR EYE SEGMENT; AQUEOUS HUMOR; CATARACT; CHOROID; CILIARY BODY; CONJUNCTIVA; CORNEA; CYTOMEGALOVIRUS INFECTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG RELEASE; DRUG RETENTION; DRUG TRANSPORT; DRY EYE; EYE; GENE THERAPY; GEOGRAPHIC ATROPHY; HUMAN; HYDROGEL; IMPLANT; IRIS; MICROEMULSION; NONHUMAN; OCULAR DRUG DELIVERY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINA MACULA LUTEA; RETINA VEIN OCCLUSION; RETINITIS; RETINITIS PIGMENTOSA; REVIEW; SCLERA; SUBRETINAL NEOVASCULARIZATION; TABLET; UVEITIS; VISCOSITY;

ANTERIOR EYE SEGMENT; CONJUNCTIVA; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; EMULSIONS; EYE DISEASES; HUMANS; INTRAVITREAL INJECTIONS; IONTOPHORESIS; OPHTHALMIC SOLUTIONS; POSTERIOR EYE SEGMENT;

EID: 84859917508     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2011.652286     Document Type: Review

References (60)

1. Diagram of the Eye. [cited March 7, 2011]; Available from: http://www.vcu.edu/eye/FAQ.html.
2. Seeley RR, Stephens TD, Tate P, editors. Anatomy and Physiology. 8 ed. New York, NY: McGraw Hill; 2008.
3. Lawrence MS, Miller JW. Ocular tissue permeabilities. Int Ophthalmol Clin. 2004;44:53-61. (Pubitemid 38955661)
4. Hillery AA, Lloyd AW, Swarbick J, editors. Drug Delivery and Targeting for Pharmacists and Pharmaceutical Scientists. New York, NY: Taylor and Francis Inc; 2001.
5. Allen LV, Popovich NG, Ansel HC, editors. Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. 8 ed. Baltimore, MD: Lippincott Williams and Wilkins; 2005.
6. Lang JC, Roehrs RE, Rodeheaver DP, Missel PJ, Jani R, Chowhan MA. Design and Evaluation of Ophthalmic Pharmaceutical Products. In: Banker GS, Rhodes CT, editors. Modern Pharmaceutics. 4 ed. New York, NY: Marcel Dekker, Inc.; 2002. pp 415-478.
7. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J. 2010;12:348-360.
8. Gaudana R, Jwala J, Boddu SH, Mitra AK. Recent perspectives in ocular drug delivery. Pharm Res. 2009;26:1197-1216.
9. Majumdar S, Hingorani T, Srirangam R, Gadepalli RS, Rimoldi JM, Repka MA. Transcorneal permeation of L- and D-aspartate ester prodrugs of acyclovir: delineation of passive diffusion versus transporter involvement. Pharm Res. 2009;26:1261-1269.
10. Karla PK, Pal D, Quinn T, Mitra AK. Molecular evidence and functional expression of a novel drug efflux pump (ABCC2) in human corneal epithelium and rabbit cornea and its role in ocular drug efflux. Int J Pharm. 2007;336:12-21. (Pubitemid 46551552)
11. Hariharan S, Gunda S, Mishra GP, Pal D, Mitra AK. Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids. Pharm Res. 2009;26:1270-1282.
12. Kaur IP, Kanwar M. Ocular preparations: the formulation approach. Drug Dev Ind Pharm. 2002;28:473-493. (Pubitemid 34680549)
13. Vandamme TF. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog Retin Eye Res. 2002;21:15-34.
14. VeriDoser Ophthalmic Delivery System. Mystic pharmaceuticals [2009 ; cited October 27, 2010]; Available from: http://www.mysticpharmaceuticals.com/ DrugDeliveryTechnology/OphthalmicDelivery.htm.
15. Veridoser delivery platform. [cited November 8, 2010]; Available from: http://www.mysticpharmaceuticals.com/DrugDeliveryTechnology/DeliveryPlatforms. htm.
16. Budai L, Hajd M, Budai M et al. Gels and liposomes in optimized ocular drug delivery: studies on ciprofloxacin formulations. Int J Pharm. 2007;343:34-40. (Pubitemid 47334864)
17. Hosny KM. Optimization of gatifloxacin liposomal hydrogel for enhanced transcorneal permeation. J Liposome Res. 2010;20:31-37.
18. Li N, Zhuang C, Wang M, Sun X, Nie S, Pan W. Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery. Int J Pharm. 2009;379:131-138.
19. Fialho SL, da Silva-Cunha A. New vehicle based on a microemulsion for topical ocular administration of dexamethasone. Clin Experiment Ophthalmol. 2004;32:626-632.
20. Peng CC, Bengani LC, Jung HJ, Leclerc J, Gupta C, and Chuahan A. Emulsions and microemulsions for ocular drug delivery. J Drug Deliv Sci Tech. 2011;21:111-121.
21. Chan J, Maghraby GM, Craig JP, Alany RG. Phase transition water-in-oil microemulsions as ocular drug delivery systems: in vitro and in vivo evaluation. Int J Pharm. 2007;328:65-71. (Pubitemid 44827562)
22. Kapoor Y, Chauhan A. Ophthalmic delivery of Cyclosporine A from Brij-97 microemulsion and surfactant-laden p-HEMA hydrogels. Int J Pharm. 2008;361:222-229.
23. De TK, Rodman DJ, Holm BA, Prasad PN, Bergey EJ. Brimonidine formulation in polyacrylic acid nanoparticles for ophthalmic delivery. J Microencapsul. 2003;20:361-374. (Pubitemid 36621477)
24. Adibkia K, Siahi Shadbad MR, Nokhodchi A et al. Piroxicam nanoparticles for ocular delivery: physicochemical characterization and implementation in endotoxin-induced uveitis. J Drug Target. 2007;15:407-416. (Pubitemid 47073056)
25. Kasseem MA, Abdel AA, Ghorab MM, Ahmed MB and Khalil RM. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm. 2007;340:126-133. (Pubitemid 47043351)
26. Products & Technologies-LX214. Lux Biosciences, Inc; [cited November 8, 2010]; Available from: www.luxbio.com/LX214. htm.
27. Rathore KS, Nema RK. Review on ocular inserts. Int J PharmTech Res. 2009;1:164-169.
28. Sahane NK, Banarjee SK, Gaikwad DD, Jadhav SL, Thorat RM. Ocular inserts: a review. DIT. 2010;2:57-64.
29. Koffler BH, McDonald M, Nelinson DS; LAC-07-01 Study Group. Improved signs, symptoms, and quality of life associated with dry eye syndrome: hydroxypropyl cellulose ophthalmic insert patient registry. Eye Contact Lens. 2010;36:170-176.
30. Jain D, Carvalho E, Banerjee R. Biodegradable hybrid polymeric membranes for ocular drug delivery. Acta Biomater. 2010;6:1370-1379.
31. Weyenberg W, Vermeire A, Dhondt MM et al. Ocular bioerodible minitablets as strategy for the management of microbial keratitis. Invest Ophthalmol Vis Sci. 2004;45:3229-3233. (Pubitemid 39121860)
32. Pijls RT, Sonderkamp T, Daube GW et al. Studies on a new device for drug delivery to the eye. Eur J Pharm Biopharm. 2005;59:283-288. (Pubitemid 40127585)
33. Pijls RT, Cruysberg LP, Nuijts RM, Dias AA, Koole LH. Capacity and tolerance of a new device for ocular drug delivery. Int J Pharm. 2007;341:152-161. (Pubitemid 47088118)
34. Lee SS, Hughes P, Ross AD, Robinson MR. Biodegradable implants for sustained drug release in the eye. Pharm Res. 2010;27:2043-2053.
35. Conference call to discuss q2 2009 financial results and latanoprost punctal plug delivery system (L-PPDS). QLT Inc; 2009; cited October 20, 2010]; Available from: http://www.qltinc.com/documents/090728-QLT-Slides.pdf.
36. QLT Inc. Conference call to discuss q22009 financial results and latanoprost punctal plug delivery system (L-PPDS). QLT Inc; 2009 [updated 2009; cited 2010 October 20 2010]; Available from: http://www.qltinc.com/documents/ 090728-QLT-Slides.pdf.
37. Bacterial conunctivitis. Ocular Therapeutix, Inc.; [2010; cited October 27, 2010]; Available from: www.ocutx.com/pipeline/drugdelivery/applications/ bacterialconjunctivitis.
38. Mitra AK, editor. Ophthalmic drug delivery systems. 2 ed. New York, NY: Marcel Dekker; 2003.
39. EyeGate pharma initiates alluvion phase iii study of egp-437 in patients with dry eye syndrome. Eyegate Pharmaceuticals, Inc; [2010; cited October 27, 2010]; Available from: http://eyegatepharma.com/pdf/news2010/EyegatePR-DES-Ph%20 III-Final.pdf.
40. Choonara YE, Pillay V, Danckwerts MP, Carmichael TR, du Toit LC. A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases. J Pharm Sci. 2010;99:2219-2239.
41. Jaffe GJ, Ashton P, Pearson PA, editors. Intraocular drug delivery. New York, NY: Taylor and Francis; 2006.
42. Therapeutic areas - retinal disorders. RXi Pharmaceuticals, Inc [2010; cited November 3, 2010]; Available from: www.rxipharma.com/therapeutic-areas/ retinal-disorder.
43. RXi Pharmaceuticals and EyeGate Pharma announce collaboration focused on non-invasive ocular delivery of RNAi Therapeutics. Business Wire; [September 22, 2010; cited October 27, 2010]; Available from: www.businesswire.com/news/home/ 20100922005477/en/RXi-Pharmaceuticals- EyeGate-Pharma-Announce-Collaboration- Focused
44. RNAi Technology. RXi Pharmaceuticals, Inc; [2010; cited November 3, 2010]; Available from: http://rxipharma.com/technology.
45. Eljarrat-Binstock E, Pe'er J, Domb AJ. New techniques for drug delivery to the posterior eye segment. Pharm Res. 2010;27:530-543.
46. Products Overview - ILUVIEN for DME. Alimera Sciences [2010; cited November 4, 2010]; Available from: http://www.alimerasciences.com/Products/ iluvien.aspx.
47. Iluvien. [cited March 7, 2011]; Available from: http://www. drugdevelopment-technology.com/projects/iluvienfordiabeticma/ iluvienfordiabeticma4.html.
48. Pearson PA. Flucinolone Insert's Impact on Overall Risk of Procedures. Retina Today. 2010 October:72-74.
49. Analysis from FAME study finds intravitreal insert effctive for treating DME at 30 months. OSN SuperSite; [2010; cited November 4, 2010]; Available from: www.osnsupersite.com/view.aspx?rid=65057
50. News & Events - FDA issues complete response letter regarding new drug application for ILUVIEN(R). pSivida Corp.
51. [Dec 23, 2010; cited January 14, 2011]; Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=168274&p=irolnewsArticle& ID=1510654&highlight=.
52. News - FDA Issues complete response letter to alimera sciences regarding new drug application for ILUVIEN(R). Alimera Sciences, Inc.; [Dec 23, 2011; cited January 14, 2011]; Available from: http://investor.alimerasciences.com/ releasedetail.cfm?ReleaseID=538819.
53. About encapsulated cell technology. Neurotech; [2010; cited November 7, 2010]; Available from: www.neurotechusa.com/ect/about-cell-technology.asp.
54. About encapsulated cell technology - NT-501. Neurotech [2010; cited November 7, 2010]; Available from: www.neurotechusa.com/ect/nt-501.asp
55. Ozurdex product. [cited March 7, 2011]; Available from: http://www.retinamaculainstitute.com/treatments/implants.
56. Verisome - Technology Overview. Icon Bioscience, Inc.; [2009; cited November 7, 2010]; Available from: www.iconbioscience.com/Technology-Overview. html
57. Pipeline - IBI-20089. Icon Bioscience, Inc.; [2009; cited November 7, 2010]; Available from: www.iconbioscience.com/IBI-20089.html
58. Technologies - Photodynamic therapy (PDT). QLT Inc; [2009; cited October 20, 2010]; Available from: www.qltinc.com/development/technologies/pdt.htm.
59. Berdugo M, Bejjani RA, Valamanesh F et al. Evaluation of the new photosensitizer Stakel (WST-11) for photodynamic choroidal vessel occlusion in rabbit and rat eyes. Invest Ophthalmol Vis Sci. 2008;49:1633-1644.
60. Safety and preliminary study of WST11 (Stakel)-Mediated VTP Therapy in subjects with CNV associated with AMD. clinicaltrials.com; [June 1, 2010; cited November 8, 2010]; Available from: http://www.clinicaltrials.gov/ct2/show/ NCT01021956?term=NCT01021956&rank=1.